NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celllung cancernon smallpancreaticmelanoma
  Phrases that lowered it: pharmacokineticslymphomaadministrationeffectclinical trial
• Sponsor's past termination rate: 16.7% (raises risk) · Sponsor's track record
• Primary purpose: other (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 59.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 24.1% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 28 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 54 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Keywords listed: 5 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 51 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 18 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer NCT00798720 · started 2008 · scored riskier than 99% of active trials completed
• HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer NCT00719875 · started 2008 · scored riskier than 63% of active trials completed
• Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer NCT01413750 · started 2010 · scored riskier than 67% of active trials terminated
• Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery NCT00662311 · started 2008 · scored riskier than 61% of active trials terminated
• Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas NCT00948688 · started 2009 · scored riskier than 88% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.